Abstract 44P
Background
Management of Her-2 negative breast cancer is evolving. Literature on response and outcomes to neoadjuvant chemotherapy (NACT) is limited from the Indian subcontinent. In this study, we evaluated the pathological complete response(pCR) rates to NACT, and outcomes in Her2-negative breast cancers, which includes TNBC and hormone receptor-positive (HR+) cohorts.
Methods
Her2-negative breast cancer patients who received neoadjuvant chemotherapy and then underwent surgery between January 2017 and December 2021 at a tertiary cancer hospital in India were included. Pathological response to chemotherapy, and outcomes were noted by retrospective electronic medical record review. pCR was defined as complete disappearance of all invasive carcinoma cells in the breast and axillary lymph nodes (ypT0/ypN0).
Results
Of the 1760 Her-2 negative breast cancers who were registered at our institute in the above time period, 232 patients received NACT, and 172 patients who completed NACT and then underwent surgery were included in the analysis. The median age of presentation was 50 years (Range 31-74 years). The median age was 46 years in the TNBC cohort, and 55 years in HR+ cohort. Majority of the patients received anthracycline/taxane based chemotherapy, and 94.1% (162/172) of the patients received all planned cycles of chemotherapy before surgery. Overall pathological complete response (pCR) was seen in 27.3% of patients (47/175). pCR rates were significantly higher in the TNBC cohort compared to HR+ cohort (38.2% vs 15.6 %, P - 0.001). TNBC variant and higher histologic grade (Grade III) were associated with significantly higher pCR rates. At a median follow-up of 30.8 months, 23.2% of patients (40/172) developed relapse (26.9% in TNBC, 19.2 % in HR+). Patients who achieved pCR had significantly lower chances of recurrence compared to those with non-pCR to chemotherapy (12.7% vs 27.2%, P- 0.045).
Conclusions
Triple-negative breast cancer subtype and higher histologic grade are associated with significantly higher pathological complete response to NACT. Achieving complete pathological response is associated with lower risk of breast cancer recurrence, and it is an important surrogate marker for recurrence-free and overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract